.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,835,501

« Back to Dashboard

Claims for Patent: 8,835,501

Title:Pharmaceutical formulations of HDAC inhibitors
Abstract: This invention pertains to pharmaceutical compositions comprising certain carbamic acid compounds (e.g., which inhibit HDAC (histone deacetylase) activity) (e.g., PXD-101, N hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide)) and one or more additional ingredients selected from cyclodextrin, arginine, and meglumine. The present invention also pertains to the use of such compositions, for example, in the inhibition of HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.
Inventor(s): Bastin; Richard J. (Waterford, IE), Hughes; Nicholas J. (Swindon, GB)
Assignee: TopoTarget UK Limited (Abingdon, Oxfordshire, GB)
Application Number:11/913,191
Patent Claims: 1. A pharmaceutical composition consisting essentially of: (a) a histone deacetylase (HDAC) inhibitor; and, (b) at least one basic in situ salt former, wherein the salt former is free arginine, meglumine or free meglumine, and, (c) a pharmaceutically acceptable excipient or carrier; wherein said HDAC inhibitor is selected from compounds of the following formula and pharmaceutically acceptable salts thereof: ##STR00022## wherein: A is a substituted or unsubstituted: C.sub.6-20carboaryl, or C.sub.5-20heteroaryl; Q.sup.1 is: a covalent bond, or a substituted or unsubstituted C.sub.1-7alkylene, C.sub.2-7alkenylene; J is: --NR.sup.N--S(.dbd.O).sub.2--, or --S(.dbd.O).sub.2--NR.sup.N--; R.sup.N is: --H, or a substituted or unsubstituted C.sub.1-7alkyl, C.sub.3-20heterocyclyl, C.sub.6-20carboaryl, C.sub.5-20heteroaryl, C.sub.6-20carboaryl-C.sub.1-7alkyl, or C.sub.5-20heteroaryl-C.sub.1-7alkyl; Q.sup.2 is a substituted or unsubstituted: C.sub.6-20carboarylene, C.sub.5-20heteroarylene, C.sub.6-20carboarylene-C.sub.1-7alkylene, C.sub.5-20heteroarylene-C.sub.1-7alkylene, C.sub.6-20carboarylene-C.sub.2-7alkenylene, C.sub.5-20heteroarylene-C.sub.2-7alkenylene, C.sub.1-7alkylene-C.sub.6-20carboarylene, C.sub.1-7alkylene-C.sub.5-20heteroarylene, C.sub.2-7alkenylene-C.sub.6-20carboarylene, C.sub.2-7alkenylene-C.sub.5-20heteroarylene, C.sub.1-7alkylene-C.sub.6-20carboarylene-C.sub.1-7alkylene, C.sub.1-7alkylene-C.sub.5-20heteroarylene-C.sub.1-7alkylene, C.sub.2-7alkenylene-C.sub.6-20carboarylene-C.sub.1-7alkylene, C.sub.2-7alkenylene-C.sub.5-20heteroarylene-C.sub.1-7alkylene, C.sub.1-7alkylene-C.sub.6-20carboarylene-C.sub.2-7alkenylene, C.sub.1-7alkylene-C.sub.5-20heteroarylene-C.sub.2-7alkenylene, C.sub.2-7alkenylene-C.sub.6-20carboarylene-C.sub.2-7alkenylene, or C.sub.2-7alkenylene-C.sub.5-20heteroarylene-C.sub.2-7alkenylene, and is unsubstituted or substituted.

2. A pharmaceutical composition according to claim 1, wherein the HDAC inhibitor is selected from the following compounds and pharmaceutically acceptable salts thereof: ##STR00023##

3. A pharmaceutical composition according to claim 1, wherein the HDAC inhibitor is selected from the following compound and pharmaceutically acceptable salts thereof: ##STR00024##

4. A pharmaceutical composition according to claim 1, wherein the HDAC inhibitor is: ##STR00025##

5. A pharmaceutical composition according to claim 3, further comprising meglumine.

6. A pharmaceutical composition according to claim 3, wherein said free arginine is: free L-arginine.

7. A pharmaceutical composition according to claim 5, wherein said meglumine is: free meglumine or a pharmaceutically acceptable salt of meglumine.

8. A pharmaceutical composition according to claim 3, wherein the molar ratio of arginine to said HDAC inhibitor is at least 0.5 to 5.

9. A pharmaceutical composition according to claim 5, wherein the molar ratio of meglumine to said HDAC inhibitor is at least 0.5 to 5.

10. A pharmaceutical composition according to claim 3, which is a liquid.

11. A pharmaceutical composition according to claim 3, which is an aqueous liquid.

12. A pharmaceutical composition according to claim 3, wherein the pharmaceutically acceptable excipient or carrier is: water-for-injection, aqueous saline solution, aqueous glucose solution, saline for injection/infusion, glucose for injection/infusion, Ringer's solution, or lactated Ringer's solution.

13. A pharmaceutical composition according to claim 3, wherein the pharmaceutically acceptable excipient or carrier is: aqueous saline solution or aqueous glucose solution.

14. A pharmaceutical composition according to claim 10, which comprises said HDAC inhibitor at a concentration of 0.1-1000 mg/mL.

15. A pharmaceutical composition according to claim 10, which comprises said HDAC inhibitor at a concentration of 30-300 mg/mL.

16. A pharmaceutical composition according to claim 10, which comprises said HDAC inhibitor at a concentration of 0.3-3000 mM.

17. A pharmaceutical composition according to claim 10, which comprises said HDAC inhibitor at a concentration of 100-500 mM.

18. A pharmaceutical composition according to claim 10, which comprises said HDAC inhibitor at a concentration of 0.01-300 mg/mL.

19. A pharmaceutical composition according to claim 10, which comprises said HDAC inhibitor at a concentration of 1.0-10 mg/mL.

20. A pharmaceutical composition according to claim 10, which comprises said HDAC inhibitor at a concentration of 0.01-100 mM.

21. A pharmaceutical composition according to claim 10, which comprises said HDAC inhibitor at a concentration of 3-30 mM.

22. A pharmaceutical composition according to claim 10, wherein said composition is suitable for parenteral administration to a patient.

23. A pharmaceutical composition according to claim 10, wherein said composition is suitable for administration to a patient by injection.

24. A pharmaceutical composition according to claim 10, wherein said composition is suitable for administration to a patient by infusion.

25. A pharmaceutical composition according to claim 3, which is a solid.

26. A pharmaceutical composition according to claim 3, which is in the form of a powder, granules, tablets, or a lyophilate/lyophilisate.

27. An intravenous (IV) infusion bag containing a pharmaceutical composition according to claim 10.

28. A vial or ampoule containing a pharmaceutical composition according to claim 10.

29. A kit comprising: (a) a pharmaceutical composition according to claim 10, provided in a suitable container with suitable packaging; and (b) instructions for use.

30. An aqueous liquid pharmaceutical composition consisting essentially of: (a) a histone deacetylase (HDAC) inhibitor; and, (b) at least one basic in situ salt former, wherein the salt former is free arginine, meglumine or free meglumine, and, (c) a pharmaceutically acceptable excipient or carrier; wherein said HDAC inhibitor is: ##STR00026##

31. A composition according to claim 30, which comprises said HDAC inhibitor at a concentration of about 50 mg/mL.

32. A composition according to claim 31, wherein the molar ratio of said L-arginine to said HDAC inhibitor is from 0.8 to 4.

33. A vial or ampoule containing a composition according to claim 31.

34. A vial or ampoule containing a composition according to claim 32.

35. An aqueous liquid pharmaceutical composition consisting essentially of: (a) a histone deacetylase (HDAC) inhibitor; (b) at least one basic in situ salt former, wherein the salt former is free arginine, meglumine or free meglumine, and, (c) a pharmaceutically acceptable excipient or carrier; and (c) water; wherein said HDAC inhibitor is: ##STR00027##

36. A composition according to claim 35, which comprises said HDAC inhibitor at a concentration of about 50 mg/mL.

37. A composition according to claim 36, wherein the molar ratio of said L-arginine to said HDAC inhibitor is from 0.8 to 4.

38. A vial or ampoule containing a composition according to claim 36.

39. A vial or ampoule containing a composition according to claim 37.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc